EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY
Status: | Completed |
---|---|
Conditions: | Hospital, Neurology |
Therapuetic Areas: | Neurology, Other |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 8/9/2017 |
Start Date: | June 2015 |
End Date: | November 2016 |
A PROSPECTIVE CLINICAL EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY
The primary objective of this study is to evaluate Ubiquitin C-terminal Hydrolase-L1 (UCH-L1)
and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of CT-positive
subjects (as determined by an independent Neuroimaging Review Committee) presenting acutely
with traumatic brain injury (Glasgow Coma Scale score 9-15).
and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of CT-positive
subjects (as determined by an independent Neuroimaging Review Committee) presenting acutely
with traumatic brain injury (Glasgow Coma Scale score 9-15).
Inclusion Criteria:
- The Subject is at least 18 years of age at screening.
- The Subject has presented to a Health Care Facility (HCF) or Emergency Department (ED)
with a suspected traumatically induced head injury, as a result of insult to the head
from an external force.
- A Glasgow Coma Scale score of 9-15 at the time of Informed Consent.
- The subject is CT-positive for acute intracranial lesion(s) based on the local
neuroradiologist's review of the subject's head CT scan.
- The CT scan and CT report used to determine eligibility must be available.
- The blood sample is collected as close to the time of head injury as possible, but no
later than 12 hours.
- The Subject or their legal representative is willing to undergo the Informed Consent
process prior to enrollment into this study
Exclusion Criteria:
- Participating in an interventional, therapeutic clinical study that may affect the
results of this study (an observational study would be acceptable).
- Time of injury cannot be determined.
- Primary diagnosis of ischemic or hemorrhagic stroke.
- Venipuncture not feasible (i.e., skin integrity compromised at the venipuncture sites,
blood vessel calcification (i.e., IV drug users, advanced atherosclerosis) both upper
limbs missing (congenital or amputee)).
- The subject has a neurodegenerative disease or other neurological disorder including
dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors.
- The subject has a history of neurosurgery within the last 30 days.
- Administration of blood transfusion after head injury and prior to the study blood
draw.
- The subject is a female who is pregnant or lactating.
- The Subject is otherwise determined by the Investigator to be an unsuitable candidate
for participation. If this criterion applies, a reason must be provided
We found this trial at
6
sites
Richmond, Virginia 23298
(804) 828-0100
Principal Investigator: V. Ramana Feeser, MD
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
Click here to add this to my saved trials
Charlottesville, Virginia 22903
(434) 924-0311
Principal Investigator: Stephen Huff, MD
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
Click here to add this to my saved trials
Detroit, Michigan 48201
Principal Investigator: Robert Welch, MD
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Frank Peacock, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
San Diego, California 92093
Principal Investigator: Raul Coimbra, MD
Click here to add this to my saved trials